NCT04504604 - TCF-001 TRACK (Target Rare Cancer Knowledge) Study | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Rare CancersCholangiocarcinomaCancer of Unknown Primary Site

Interventions

DIAGNOSTIC_TEST

FoundationOne CDx and FoundationOne Liquid CDx

Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.

Trial Locations (1)

02139

RECRUITING

TargetCancer Foundation, Cambridge